Trials / Unknown
UnknownNCT05354089
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety, tolerability, immunogenicity and immune persistence of SYS6006 (SARS-CoV-2 mRNA Vaccine) in 18-59 year old healthy population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 20 μg dose of SYS6006 | 20 μg dose of SYS6006 vaccine IM on day 0 and day 21. |
| BIOLOGICAL | 30 μg dose of SYS6006 | 30 μg dose of SYS6006 vaccine IM on day 0 and day 21. |
| DRUG | Placebo | Placebo IM on day 0 and day 21. |
Timeline
- Start date
- 2022-04-27
- Primary completion
- 2022-07-09
- Completion
- 2023-10-01
- First posted
- 2022-04-29
- Last updated
- 2023-05-24
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05354089. Inclusion in this directory is not an endorsement.